People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lusaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $60.2M | $955.7M | 2022 |
| Superluminal Medicines, Inc. | — | Biotechnology | Series B | $50.7M | $22.1M | 2023 |
CATHERINE RIESEN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside CATHERINE RIESEN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 2 | 17 |
| Dylan Morris | 1 | 8 |
| DANIEL GRAU | 1 | 3 |
| Ramin Farzaneh-Far | 1 | 3 |
| Neil Buckley | 1 | 3 |
| CONY D'CRUZ | 1 | 2 |
| DIAMANTIS XYLAS | 1 | 2 |
| CRAIG RANDALL | 1 | 1 |
| Edward Monaghan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.